or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    NVO D 2.37 1.99
    ASML F 0.11 1.25
    UL D 1.70 1.10
    NVS D 0.41 1.06
    AZN D 2.13 1.04
    TM D 0.59 0.76
    RY A -0.01 0.71

    Represented by ETF Holdings

    Keywords: Drugs Inflammation Nasdaq 100 Neuroscience Primary Care Acid Active Pharmaceutical Ingredients Anemia Angina Animal Health Anti Diabetic Drugs Antibiotics Antibodies Argon Asset Management Products Asthma Auto Parts Autoimmune And Inflammatory Disease Automotive Industry Bank
    Industries: Drug Manufacturers - Major Auto Manufacturers Banks - Global Biotechnology Household & Personal Products Semiconductor Equipment & Materials

    Recent News for Dimensional International Sustainability Core 1 ETF & its Holdings

    Date Stock Title
    Nov 22 NVS Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View
    Nov 22 AZN Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View
    Nov 22 NVS Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics
    Nov 22 NVO “No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl
    Nov 22 UL Unilever CEO says will slim down, not spin off food business - FT
    Nov 22 NVO Novo Nordisk Plunges 25% in 3 Months: How to Play the Stock
    Nov 22 NVO Barclays says buy Novo Nordisk stock 'into this critically important catalyst'
    Nov 22 NVO RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?
    Nov 22 NVO Novo Nordisk said to have contracted Ypsomed to make next gen obesity drug’s pens
    Nov 22 NVS Novartis provides updates to mid-term guidance, now sees 6% sales CAGR 2023-2028
    Nov 22 NVO Oura rings to track blood sugar, Vaccines vs RFK Jr., and Ozempic 2.0: Pharma news roundup
    Nov 22 NVS Novartis acquires Kate Therapeutics to advance gene therapies
    Nov 21 NVO The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock.
    Nov 21 NVO Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
    Nov 21 AZN AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns
    Nov 21 NVS Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline
    Nov 21 NVS Novartis buys gene therapy developer Kate for up to $1.1B
    Nov 21 AZN Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
    Nov 21 TM Experts: These 5 Car Brands Are the Cheapest To Maintain
    Nov 21 TM Toyota Releases 2024 North American Environmental Sustainability Report
    The Portfolio is designed to purchase a broad and diverse group of securities of non-U.S. companies in developed markets. The Portfolio invests in companies of all sizes, with increased exposure to smaller capitalization, lower relative price, and higher profitability companies as compared to their representation in the International Universe, while adjusting the composition of the Portfolio based on sustainability impact considerations.
    Back to the Main DFSI Page...